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ABSTRACT
Background: Interventions are needed to address iron deficiency in low-income settings.
Objective: This secondary outcome analysis aimed to compare the hemoglobin (Hb) and iron status [zinc protoporphyrin
(ZPP)] of children born to women enrolled in the iLiNS-DYAD trial in Ghana.
Methods:Women≤20wk pregnant (n= 1320) were assigned to receive 60mg Fe/d and 400 µg folic acid/d until delivery
and placebo thereafter, and no supplementation for infants (IFA group); or multiple micronutrients containing 20 mg Fe/d
until 6 mo postpartum and no supplementation for infants (MMN); or small-quantity lipid-based nutrient supplements
(SQ-LNSs) containing 20 mg Fe/d until 6 mo postpartum, and SQ-LNSs for infants from 6 to 18 mo of age (LNS). We
compared infants’ Hb (g/L) and ZPP (µmol/mol heme) at 6 and 18 mo of age.
Results: At 6 mo of age, groups did not differ in mean ± SD Hb (overall: 113 ± 9.9 g/L) or geometric mean (95% CI) ZPP
[overall: 62.6 (60.6, 64.7)]. At 18 mo of age, mean ± SD Hb (overall: 112 ± 10.4 g/L) did not differ significantly between
groups, whereas geometric mean (95% CI) ZPP was lower (P = 0.031) in the LNS group [53.9 (50.7, 57.3)] than the IFA
[60.4 (56.7, 64.3)] but not the MMN [58.8 (55.6, 62.2)] group. Further, the LNS group, compared with the IFA and MMN
groups combined, had a lower prevalence of elevated (>70) ZPP (27.5% compared with 35%; P = 0.02) and a marginally
lower prevalence of anemia (38.7% compared with 44.9%; P = 0.06). These results generally remained unchanged
when controlling for prespecified covariates or correcting for inflammation.
Conclusions: In this setting, providing SQ-LNSs or multiple micronutrients with 20 mg Fe/d, compared with iron
(60 mg/d) and folic acid, to pregnant women does not affect their infants’ Hb or iron status at 6 mo of age, but maternal
and infant supplementation with SQ-LNSs increases infants’ iron status at 18 mo of age. This trial was registered at
clinicaltrials.gov as NCT00970866. J Nutr 2019;149:149–158.
Keywords: micronutrient supplementation, iron and folic acid, multiple micronutrient supplements, small-quantity
lipid-based nutrient supplements, infants
Introduction
Inadequate micronutrient intake is common in low-income
countries (1) and has been associated with increased risk
of perinatal morbidity and mortality (2), low birth weight
(3), and poor child growth and development (4). Conse-
quently, addressing the micronutrient needs of women and
children especially during the “first 1000 d” is a global
priority (5–7).
As part of the International Lipid-based Nutrient Sup-
plements (iLiNS) Project, we developed small-quantity lipid-
based nutrient supplements (SQ-LNSs), which can be used
to enrich home-prepared foods for women and children (8),
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and thereby increase the intakes of essential nutrients without
causing substantial changes in usual dietary practices. During
the last several years, similar or different formulations of SQ-
LNS products (9) have been used in many intervention trials
and programs worldwide (10).
In the iLiNS-DYAD randomized, controlled supplementation
trial in Ghana, we evaluated the efficacy of SQ-LNSs given
to women during pregnancy and the first 6 mo postpartum,
and to their offspring from 6 to 18 mo of age, based on
evidence that child malnutrition in developing countries often
begins in utero and continues after birth (11). We previously
reported the primary growth outcomes (12, 13) as well as
several other secondary outcomes (14–18) of the trial and
showed that maternal–infant supplementation with SQ-LNSs,
compared with maternal-only supplementation with iron and
folic acid or multiple micronutrients, promoted infant and child
growth in our trial setting.
In West Africa, an estimated 80% of children <5 y of age
are anemic (19), up to one-half of which are estimated to be due
to iron deficiency (20). Possible consequences of iron deficiency
anemia (IDA) include cognitive impairment in children (21)
and lower school performance (22). In this present analysis of
secondary outcomes of the trial, we aimed to determine the
impact of the iLiNS-DYAD intervention on children’s blood
hemoglobin (Hb) and iron status and inflammation biomarkers
at 6 and 18 mo of age.
Methods
Study setting, design, and participants
The iLiNS-DYAD Ghana trial (NCT00970866) has been described
in detail previously (12–14). Briefly, the trial was conducted in the
Somanya–Odumasi–Kpong area, a semiurban setting ∼70 km north
of Accra, and was designed as a partially double-blind, individually
randomized, controlled trial with 3 equal-size groups. Women ≥18
y old and ≤20 wk pregnant identified from antenatal clinics were
recruited after obtaining informed consent for themselves and for their
infants upon delivery. Exclusion criteria were: not considered as a
resident of the area, intention to move out of the area, milk or peanut
allergy, participation in another trial, HIV infection, asthma, epilepsy,
tuberculosis, any malignancy, or unwillingness to receive fieldworkers
or take the study supplement.
The trial was approved by 3 ethics committees (University of
California, Davis; Ghana Health Service; and Noguchi Memorial
Institute for Medical Research) and monitored by a Data and Safety
Monitoring Board.
Supported by Bill & Melinda Gates Foundation grant OPP49817 to the
University of California, Davis (to KGD).
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Group assignments and blinding
As reported previously (12–14), recruited women who remained eligible
were, after baseline assessments, randomly assigned to consume 60 mg
Fe + 400 µg folic acid/d (IFA supplement or group), multiple micronu-
trients containing 18 vitamins and minerals (MMNs supplement or
group), or 20 g SQ-LNS/d (LNS group) during pregnancy. In the first
6 mo postpartum, women in the IFA group were assigned 200 mg Ca/d
as placebo, and those in the MMN and LNS groups assigned the same
supplements as during pregnancy. From 6 to 18 mo of age, infants born
to women in the IFA and MMN groups were assigned to receive no
micronutrient supplementation, whereas those of women in the LNS
group were assigned to consume SQ-LNSs designed for infants. The
IFA and MMN supplements were provided as capsules in blister packs
of 10, whereas the SQ-LNS for women was in 20-g sachets, and that for
infants in 10-g sachets (given 2/d).
The following individuals completed the group assignments (12,
13, 17): 1) the Study Statistician at UC Davis, Janet M Peerson,
developed the allocations in blocks of 9 (SAS for Windows version 9.4);
2) someone at the University of Ghana not involved in the recruitment
of subjects prepared the envelopes containing the assignments, which
were numbered and stacked by block number; and 3) the Study Nurse
at the field site performed the random assignment. At each enrollment,
the Study Nurse shuffled 9 envelopes taken from the top of the stack
and asked the participant to make a pick to reveal the assignment. The
Nurse then returned the unused envelopes to the top of the stack.When
there were <9 women left to be enrolled, the Nurse shuffled whatever
number of envelopes remained. Any allocation information was kept
securely by the Field Supervisor in Ghana and the Study Statistician at
UC Davis only.
At enrollment, the Study Nurse gave women a 2-wk supply of
supplements, advice to take 1 capsule/d with water after a meal, or
one 20-g SQ-LNS sachet/d mixed with food, and a standard nutrition
message about the need to “eat meat, fish, eggs, fruits, and vegetables”
whenever possible (12, 13). The IFA and MMN capsules were known
to the study team and participants only by their color codes (3 colors
for IFA and 3 for MMN). It was not possible to blind study workers
and participants to the capsules and the LNSs owing to their apparent
differences, but laboratory staff and data analysts had no knowledge of
the group assignments.
Follow-up
During pregnancy, fieldworkers visited women in their homes biweekly
to deliver supplements. All live-born singleton infants delivered by the
women were enrolled into the study. In cases of multiple births, only
1 infant was selected randomly, and the selected infant was enrolled if
he or she was born alive. After women gave birth, fieldworkers visited
them and their infants weekly, but delivered the women’s supplements
or placebo biweekly as before.
Women exited the study at 6 mo postpartum, but the weekly visits
for the infants continued. At 6 mo of age, the Study Nurse delivered
the “minimum message” on complementary feeding to all mothers at
the laboratory after the infants’ first laboratory assessment: “Breastfeed
your baby as you did before 6 mo of age; do not forget to feed your
baby meat, fish, eggs, fruits and vegetables whenever you can.” During
the next usual weekly home visit, fieldworkers delivered the first supply
of SQ-LNSs for infants in the LNS group, advised those mothers or
caregivers on how to feed the supplements (i.e., mix the entire content
of 1 sachet with 2–3 tablespoons of food for the infant before feeding
additional foods if the infant desires, 2 times/d), and repeated the
“minimum message” on complementary feeding given by the Study
Nurse. For infants in the IFA and MMN groups who were not assigned
to any supplements, fieldworkers also repeated the “minimummessage”
to their mothers or caregivers. Fieldworkers delivered a fresh supply
of infants’ SQ-LNSs during the usual weekly visits, but the “minimum
message” was not repeated again thereafter. Infants exited the study at
18 mo of age.
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Trial supplements
As previously reported (8, 12–14, 16), the IFA reflected the Ghana
Health Service’s standard micronutrient supplementation for pregnant
women in Ghana at the time of the study (23). The daily dose of
MMN contained 18 vitamins and minerals at 1 or 2 times the RDA
for pregnancy, except iron. For iron, we used 20 mg/d instead of the
30 mg/d in the UNICEF/WHO/United Nations University International
Multiple Micronutrient Preparation (UNIMMAP) formulation (24) or
the 30–60 mg/d in the WHO guideline (23), because of previous
evidence (25) showing that 20 mg Fe/d was just as effective as
40 mg/d or 80 mg/d in treating anemia during pregnancy and was likely
to cause fewer gastrointestinal side effects compared with a 30–60 mg/d
dosage. The SQ-LNS for women had similar micronutrient contents to
the MMN, plus energy, protein, and essential fatty acids as well as the
maximum amounts of calcium,magnesium, phosphorus, and potassium
that could be included given technical and organoleptic constraints.
Including 20 mg Fe/d in the SQ-LNS for women made it possible to
have just one product for both pregnancy and lactation, assuming that
this amount, in addition to iron from the usual diet, would give a total
daily intake that was close to the amount in the UNIMMAP formulation
(24) and would therefore meet the RDA of 27 mg Fe for pregnancy,
while at the same time not greatly exceeding the RDA (9 mg/d) for
lactation (8).
The SQ-LNS for infants was designed to generally supply the
WHO/FAO Recommended Nutrient Intake for key micronutrients for
infants 7–12 mo of age, with a few exceptions (8). We used an iron
dosage (6 mg/d) that was approximately the WHO/FAO Recommended
Nutrient Intake for infants 7–12 mo of age when assuming high
bioavailability (6.2 mg/d), and 33% lower than the dosage previously
used in Ghana (26), because of concerns about increasing the risk of
malaria and infections in an area of high malaria endemicity (27). Zinc
content (8 mg/d) was kept higher (8, 28) than the 4 mg/d used in our
previous study (26) because zinc absorption may be decreased in the
study area’s predominantly maize-based diet high in phytate.
Data collection
Women’s baseline assessments included sociodemographic character-
istics; gestational age (by using ultrasound biometry, Aloka SSD
500); anthropometric status [by using standard procedures (29)];
venous blood Hb concentration (HemoCue Hb301; Hemocue AG);
zinc protoporphyrin concentration (ZPP) (Hematofluorometer; Aviv
Biomedical Co.); and peripheral malaria parasitemia (Vision Biotech)
(13).Hb concentration wasmeasured within 2min after the blood draw.
We used the original Aviv cover-slides and 3-level control material for
the ZPP measurements, after red blood cells were washed 3 times with
normal saline. Women’s supplement intakes were monitored biweekly
by collecting unused blister packs or SQ-LNS sachets at each visit. In
addition, during the biweekly interviews, women were asked on how
many days since the last visit they had consumed the supplements,
reasons (if any) they did not consume the supplements, and, for those
in the LNS group, whether someone else had consumed some of
the supplements. Any discrepancies between the responses to these
questions and the number of capsules or sachets remaining since the
last visit were resolved during the interview.
For infants in the LNS group, supplement intakes were monitored
weekly by training mothers to use a calendar grid to indicate, on a daily
basis, whether infants consumed the supplement. Calendar grids were
checked at each weekly visit. Mothers unable to use the calendar grid
were asked to recall the children’s supplement intakes for each day since
the last visit. In addition, fieldworkers collected any unused SQ-LNS
sachets at each visit, and reconciled the number of sachets remaining
since the last visit with the consumption information recorded on the
calendar grid or provided by the mother. At 6 and 18 mo of age, infants
were brought to the laboratory, where we collected venous blood, and
measured Hb concentration within 2 min, as well as measuring ZPP
concentrations and peripheral malaria parasitemia for all infants using
the same techniques used for the women. The infants’ plasma samples
obtained after centrifuging the blood at 1252 × g for 15 min at a
room temperature of ∼23°C were stored in Ghana at −33°C, before
being air-freighted on dry ice to the USDA Western Human Nutrition
Research Center (WHNRC) in Davis, CA, where we determined the C-
reactive protein (CRP) and α-1 glycoprotein (AGP) concentrations in a
randomly selected subsample of infants by using a Cobas Integra 400
plus Automatic Analyzer (Roche Diagnostic Corp.).
The secondary outcomes evaluated herein were infants’ Hb (grams
per liter), ZPP (micromoles per mole of heme), CRP (milligrams per
liter), and AGP (grams per liter) concentrations at 6 and 18 mo of age,
and the percentages of infants with anemia (indicated by low Hb), iron
deficiency (indicated by elevated ZPP), and IDA (low Hb plus elevated
ZPP) at 6 and 18 mo of age.
Sample size and data analysis
As described previously (12, 13), the sample size for the iLiNS-DYAD-
Ghana study was based on detecting an effect size or Cohen’s d (30)
of 0.3 between any 2 groups for any continuous variables, with a 2-
sided 5% test and 80% power. We previously reported the temporary
mislabeling of some IFA and MMN supplements (12, 13), as a result
of which 170 women in the IFA group inadvertently received MMN
capsules either throughout (n = 85) or during part of (n = 85) their
pregnancy before receiving the intended IFA capsules, and 170 women
in the MMN group received IFA capsules either throughout (n = 78) or
during part of (n = 92) their pregnancy before receiving the intended
MMN capsules. In total, 1320 women were enrolled.
This present analysis includes all of the children for whom data were
available, consistent with our analysis of the primary growth outcomes
(12). For CRP and AGP analyses (as well as several other biochemical
outcomes in the trial), however, the target sample size was based on
detecting an effect size of ≥0.5 between any 2 groups, with a 2-sided
5% test and 80% power. This required 105 subjects/group, or 315
subjects for the 3 groups, after taking into account ≤25% attrition.
The subsample for the CRP and AGP analyses was selected from the
children whose mothers had not been pregnant during the period when
the temporary mislabeling occurred.
The analysis reported herein was part of the iLiNS-DYAD-Ghana
statistical analysis plan, which we posted at our website (www.ilins.org)
before data analysis began. Both the statistical analysis plan and the
trial protocol at clinicaltrials.org listed children’s blood Hb and iron
status as secondary outcomes to be analyzed separately from the
primary outcomes. We used Hb <100 g/L to define anemia in women
(14, 31, 32). For children, we defined anemia by using the cutoff of
Hb <110 g/L according to the WHO (32, 33), as well as by the cutoff
values of Hb<105 g/L for 6 mo of age described by Domellöf et al. (34),
and Hb <100 g/L for 18 mo of age (31) described by the International
Nutritional Anemia Consultative Group (INACG), because of concerns
that the WHO cutoff may be set too high. We defined elevated ZPP as
ZPP >70 µmol/mol heme (35–37); elevated CRP as CRP >5.0 mg/L
(38); and elevated AGP as AGP >1.0 g/L (38). Infants’ Hb values were
considered to be normally distributed, but the ZPP, CRP, and AGP
values (Shapiro–Wilk W <0.95 in all cases) were ln-transformed before
analysis.
We analyzed data on an intention-to-treat basis (by including
children regardless of adherence to treatment), using SAS for Windows
version 9.4 (SAS Institute). Background maternal and household vari-
ables were summarized by intervention groups based on supplements
women were intended to receive when enrolled. Because of the protocol
violation associated with the consumption of mislabeled IFA or MMN
capsules, we analyzed our data by using 2 scenarios, as done previously
(12): in the first, intervention groups were based on the supplements
women were intended to receive when enrolled; in the second, groups
were based on the supplements women actually received when enrolled.
In addition, we performed a secondary analysis by using a 2-group
comparison in which the IFA and MMN groups were combined and
compared with the LNS group (12).
We analyzed continuous and binary outcomes at 6 and 18 mo
of age, by using linear and logistic regression models (SAS, PROC
GLIMMIX), with Tukey–Kramer adjustment for multiple comparisons.
We compared group means ± SDs (or SEs) or geometric means (95%
CIs) for continuous outcome measures, and group percentages (95%
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TABLE 1 Characteristics of women (n = 1320) enrolled in the iLiNS-DYAD-Ghana nutrient supplementation trial, by group according
to the supplements women were intended to receive when enrolled1
Background characteristics IFA (n = 441) MMN (n = 439) LNS (n = 440)
Age, y 27 ± 5 (441) 27 ± 6 (439) 27 ± 6 (440)
Formal education, y 8 ± 4 (441) 8 ± 4 (439) 8 ± 4 (440)
Gestational age at enrollment, wk 16.2 ± 3.3 (438) 16.0 ± 3.2 (438) 16.1 ± 3.3 (435)
Asset index2 0.05 ± 1.01 (433) 0.05 ± 0.99 (431) –0.09 ± 1.00 (432)
Housing index2 0.05 ± 0.98 (433) –0.03 ± 1.02 (431) –0.01 ± 1.00 (432)
HFIAS score3 2.8 ± 4.6 (436) 2.4 ± 4.1 (429) 2.6 ± 4.0 (432)
Married or cohabiting, n/N (%) 406/441 (92.1) 413/439 (94.1) 405/440 (92.0)
Primiparous women, n/N (%) 162/441 (36.7) 137/439 (31.2) 147/440 (33.4)
Positive for malaria at baseline,4 n/N (%) 40/441 (9.1) 39/438 (8.9) 54/440 (12.3)
Positive for malaria at 36 wk,4 n/N (%) 30/348 (8.6) 34/362 (9.4) 38/336 (11.3)
Anemic at baseline,5 n/N (%) 55/441 (12.5) 70/438 (16.0) 60/440 (13.6)
Anemic at 36 wk,5 n/N (%) 13/349 (3.7) 23/362 (6.4) 27/338 (8.0)
1Values are means ± SDs (N) or n/N (%). HFIAS, Household Food Insecurity Access Scale; IFA, Iron and Folic Acid group randomly assigned to receive 60 mg Fe/d and 400 mg
folic acid/d during pregnancy and 200 mg Ca/d as placebo during the first 6 mo postpartum; iLiNS, International Lipid-based Nutrient Supplements; LNS, Lipid-based Nutrient
Supplement group randomly assigned to receive 20 g small-quantity Lipid-based Nutrient Supplements/d with the same micronutrients as the MMN group, plus 4 more minerals
(calcium, phosphorus, potassium, and magnesium) and macronutrients until 6 mo postpartum; MMN, Multiple Micronutrient group randomly assigned to receive 18 vitamins
and minerals, including 20 mg Fe, daily until 6 mo postpartum; n, number of participants identified as “yes” for the variable in question; N, total number of participants in the
group in question.
2Proxy indicators for household socioeconomic status; higher values represent higher socioeconomic status.
3HFIAS score is a proxy indicator for household food insecurity (42); higher values represent higher food insecurity.
4Rapid diagnostic test (Clearview Malarial Combo; Vision Biotech).
5Anemia defined as blood hemoglobin concentration <100 g/L (31, 32, 43).
CIs) for binary outcomes. Along with group comparisons, we estimated
contrasts between groups (effect size) and their 95% CIs (39), including
difference in means and ratio of log-transformed means for continuous
outcomes, and RRs (40) for binary outcomes.
Both unadjusted and adjusted analyses were performed. In the
adjusted analyses, only prespecified potential covariates (maternal age,
height, BMI, education, gestational age at enrollment, primiparity,
season at enrollment, baseline anemia status, and proxy indicators for
household socioeconomic status and child sex) significantly associated
with the outcome at α = 0.1 in bivariate analyses were included in
the final models. For binary outcomes, the adjusted percentages were
generated by using the technique described by Kleinman and Norton
(41).
In the subsample of children for whom there were CRP and AGP
data, we performed a sensitivity analysis as done previously (14), by
correcting for the effect of inflammation (CRP and AGP) on the Hb and
iron status outcomes (38) and repeating the above analyses. We used
3 inflammation categories, namely: reference (normal CRP and AGP),
incubation (raised CRP and normal AGP), and early (raised CRP and
AGP) or late (normal CRP and raised AGP) convalescence, to calculate
the corrected Hb and ZPP values (44).
We have presented statistics in the text as means ± SDs or
geometric means (95% CIs) for continuous outcomes, and percentages
for binary outcomes. As we published previously, the self-reported
adherence to supplement intake for women (pregnancy/lactation) was
88.1%/85.7% for the IFA group, 87.0%/85.0% for the MMN group,
and 83.7%/80.0% for the LNS group (45), and that for the infants in
the LNS group was 73.5% (12).
Results
Data were collected between December 2009 and March 2014.
In total, 1320 women were enrolled. At baseline, the women
were ∼27 y of age on average, had ∼8 y of formal education,
and were at ∼16 weeks of gestation (Table 1); 10% tested
positive in the rapid diagnostic test for malaria, and 14% had
Hb <100 g/L.
We enrolled 1228 infants at birth out of 1257 deliveries;
infants from 29 deliveries who were stillborn could not be
enrolled (Figure 1). In all, 1197 infants attended the laboratory
visit at 6 mo of age, and 1185 of the 1228 enrolled completed
the study at 18 mo of age. The reasons some infants did not
complete the study were death (n= 27), parental refusal (n= 9),
and relocation from the study site (n = 7). Only 1.4% of infants
at 6 mo of age and 1.1% at 18 mo of age had positive results in
the rapid diagnostic test for malaria; these results did not differ
by group at either of the 2 time points.
Overall, the children’s mean ± SD Hb concentration was
113 ± 9.9 g/L at 6 mo of age and 112 ± 10.4 g/L at 18 mo of
age, whereas the geometric mean (95% CI) ZPP concentration
was 62.6 µmol/mol heme (60.6, 64.7 µmol/mol heme) at
6 mo of age and 57.6 µmol/mol heme (55.7, 59.7 µmol/mol
heme) at 18 mo of age. When using the WHO cutoff (32,
33), the prevalence of anemia was 35.3% at 6 mo of age and
42.9% at 18 mo of age, whereas the prevalence of IDA was
19.1% at 6 mo of age and 21.0% at 18 mo of age. When using
the cutoffs described by Domellöf et al. (34) and the INACG
(31), however, the overall prevalences of anemia (18.6% at
6 mo of age; 5.2% at 18 mo of age) and IDA (11.9% at
6 mo of age; 3.9% at 18 mo of age) were much lower.
Group comparisons
In the unadjusted analyses of continuous outcomes (Table 2),
mean Hb and geometric mean ZPP concentrations at 6 mo of
age did not differ by intervention group, but geometric mean
CRP and AGP were significantly lower in the IFA and LNS
groups than in the MMN group. At 18 mo of age, mean
Hb and geometric mean CRP and AGP concentrations did
not differ by intervention group, but geometric mean ZPP
concentration was lower in the LNS group compared with
the IFA, but not the MMN group, whereas the IFA and
MMN groups did not differ in any of these outcomes. In
the secondary analysis in which the IFA and MMN groups
were combined (Supplemental Table 1), geometric mean (95%
CI) ZPP concentration at 18 mo of age was significantly
lower (P = 0.008) in the LNS group [53.9 µmol/mol heme
(50.7, 57.3 µmol/mol heme)] than in the IFA + MMN group
[59.6 µmol/mol heme (57.1, 62.1 µmol/mol heme)].
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FIGURE 1 Study profile showing infants whose mothers were enrolled into the trial, and the reasons some infants were lost to follow-up.
IFA, Iron and Folic Acid group: infants were assigned to receive no supplements, their mothers were assigned to receive 60 mg Fe/d and 400
µg folic acid/d during pregnancy and 200 mg Ca/d as placebo during the first 6 mo postpartum; LNS, Lipid-based Nutrient Supplement group:
infants were assigned to receive 20 g Lipid-based Nutrient Supplement/d (designed for infants) containing 6 mg Fe/d from 6 to 18 mo of age,
their mothers received 20 g Lipid-based Nutrient Supplement/d (designed for women) with the same micronutrients as the MMN group during
pregnancy and the first 6mo postpartum—both Lipid-based Nutrient Supplement products contained 4 additional minerals (calcium, phosphorus,
potassium, and magnesium) as well as macronutrients; MMN, Multiple Micronutrient group: infants were assigned to receive no supplements,
their mothers were assigned to receive a multiple micronutrient capsule containing 18 vitamins and minerals, including 20 mg Fe, daily during
pregnancy and the first 6 mo postpartum.
In the unadjusted analyses of binary outcomes (Table 3),
there was a trend (P = 0.07) towards a lower prevalence of
elevated ZPP in the LNS group than in the other 2 groups at
18 mo of age when groups were based on supplements women
were intended to receive when enrolled; when groups were
based on supplements women actually received when enrolled,
the prevalence of elevated ZPP at 18 mo of age was significantly
lower in the LNS group than in the other 2 groups, which
did not differ in this outcome regardless of how groups were
analyzed. The intervention groups did not differ in any of the
other binary outcomes. In the secondary analysis (Supplemental
Table 2), children in the LNS group had a marginally lower
prevalence of anemia (38.7% compared with 44.9%; P = 0.06)
based on the WHO cutoff, and a significantly lower RR (95%
CI) of elevated ZPP [0.79 µmol/mol heme (0.64, 0.97 µmol/mol
heme); P = 0.02] at 18 mo of age compared with the IFA and
MMN groups combined.
The results were unchanged in the adjusted analyses (data
not shown), except for the prevalence of elevated ZPP, in which
case the difference between the LNS group and the other 2
groups became nonsignificant, although the point estimates
were consistent with the unadjusted results. Finally, in the
sensitivity analysis in which Hb and ZPP values were corrected
for inflammation in a subsample (Supplemental Table 3), the
geometric mean (95% CI) ZPP concentration at 18 mo of
age was significantly lower (P = 0.044) in the LNS group
[53.9 µmol/mol heme (50.7, 57.3 µmol/mol heme)] than in
the IFA [59.6 µmol/mol heme (56.2, 63.3 µmol/mol heme)] or
the MMN [59.5 µmol/mol heme (56.0, 63.1 µmol/mol heme)]
group, whereas the IFA and MMN groups did not differ in this
outcome.None of the binary outcome measures generated from
the inflammation-corrected Hb and ZPP values (Supplemental
Table 4) differed between the 2 intervention groups.
Discussion
We found that supplementation of women’s diet with 60 mg
Fe/d and 400 µg folic acid/d during pregnancy and placebo
in the first 6 mo postpartum, or multiple micronutrient
supplements or SQ-LNSs containing 20 mg Fe/d during both
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TABLE 2 Unadjusted continuous outcome measures (hemoglobin and biomarkers of iron status and inflammation) for infants in the
iLiNS-DYAD randomized trial of daily nutrient supplementation in a semiurban setting in Ghana, by intervention group1
Intervention group based on supplements mothers
were intended to receive when enrolled
Intervention group based on supplements mothers
actually received when enrolled
Outcome variable
IFA
(n = 441)
MMN
(n = 439)
LNS
(n = 440) P2
IFA
(n = 441)
MMN
(n = 439)
LNS
(n = 440) P2
Hemoglobin, g/L
6 mo 113 ± 11 (310) 113 ± 10 (325) 114 ± 10 (313) 0.72 114 ± 10 (308) 112 ± 10 (327) 114 ± 10 (313) 0.17
18 mo 112 ± 11 (333) 112 ± 11 (328) 113 ± 10 (328) 0.21 112 ± 11 (321) 112 ± 10 (340) 113 ± 10 (328) 0.19
ZPP, µmol/mol heme
6 mo 62.8 (59.1, 66.7)
[300]
61.5 (58.3, 65.0)
[316]
63.5 (60.0, 67.1)
[299]
0.49 60.8 (57.3, 64.5)
[301]
63.4 (60.0, 67.1)
[315]
63.5 (60.0, 67.1)
[299]
0.74
18 mo 60.4 (56.7, 64.3)b
[329]
58.8 (55.6, 62.2)ab
[323]
53.9 (50.7, 57.3)a
[320]
0.031 59.6 (56.2, 63.3)b
[317]
59.5 (56.0, 63.1)ab
[335]
53.9 (50.7, 57.3)a
[320]
0.026
CRP, mg/L
6 mo 0.32 (0.22, 0.46)a
[102]
0.65 (0.43, 0.99)b
[100]
0.41 (0.28, 0.60)ab
[101]
0.033 — — —
18 mo 0.58 (0.39, 0.84)
[101]
0.71 (0.50, 1.01)
[101]
0.94 (0.63, 1.42)
[100]
0.19 — — —
AGP, g/L
6 mo 0.80 (0.75, 0.86)ab
[102]
0.90 (0.84, 0.97)b
[100]
0.80 (0.74, 0.86)a
[101]
0.027 — — —
18 mo 0.96 (0.89, 1.04)
[101]
0.94 (0.88, 1.00)
[101]
1.03 (0.96, 1.11)
[100]
0.17 — — —
1All supplements were intended for daily consumption. The subsample for the CRP and AGP analyses was selected from the children whose mothers were not pregnant during
the period when the temporary mislabeling occurred. Results are based on ANOVA (SAS PROC GLIMMIX). Values for hemoglobin are means ± SDs (number of participants
analyzed for the outcome); values for ZPP, CRP, and AGP are geometric means (95% CIs) [number of participants analyzed for the outcome in question]. For each analysis scenario,
values in the same row without a common superscript letter are significantly different at α = 0.05. AGP, α-1 acid glycoprotein; CRP, C-reactive protein; IFA, Iron and Folic Acid
group: infants were assigned to no supplements, their mothers were assigned to receive 60 mg Fe/d and 400 µg folic acid/d during pregnancy and 200 mg Ca/d as placebo
during the first 6 mo postpartum; iLiNS, International Lipid-based Nutrient Supplements; LNS, Lipid-based Nutrient Supplement group: infants were assigned to receive 20 g
Lipid-based Nutrient Supplement/d (designed for infants) containing 6 mg Fe/d from 6 to 18 mo of age, their mothers received 20 g Lipid-based Nutrient Supplement/d (designed
for women) with the same micronutrients as the MMN group during pregnancy and the first 6 mo postpartum—both Lipid-based Nutrient Supplement products contained
4 additional minerals (calcium, phosphorus, potassium, and magnesium) as well as macronutrients; MMN, Multiple Micronutrient group: infants were assigned to receive no
supplements, their mothers were assigned to receive a multiple micronutrient capsule containing 18 vitamins and minerals, including 20 mg Fe, daily during pregnancy and the
first 6 mo postpartum; ZPP, zinc protoporphyrin.
2P values compare the means or geometric means of 3 groups, with Tukey–Kramer adjustment for pairwise comparisons.
periods, did not result in differences in infant Hb or iron status
at 6 mo of age. However, infants who consumed SQ-LNSs from
6 to 18 mo of age, after their mothers had been given SQ-LNSs
during pregnancy and lactation, had greater iron supply for Hb
synthesis and marginally lower prevalence of anemia than their
counterparts who did not consume any supplements from 6
to 18 mo of age and whose mothers consumed iron and folic
acid during pregnancy only, or multiple micronutrients during
pregnancy and lactation.
We previously reported the main weaknesses of our
study, including the inability to blind the study women and
fieldworkers to who was in the LNS group (in which women
and children received SQ-LNSs) and who was in the non-LNS
groups (in which women received IFA or MMN capsules and
children received no supplementation), assessment of adherence
to supplement intakes via maternal reporting rather than
through direct observation, and the exposure of 340 women in
the IFA and MMN groups to unintended supplements during
all or part of pregnancy (12, 13). Further, determining CRP
and AGP in a subsample may have limited our ability to detect
significant differences among groups in the sensitivity analysis
in which we corrected for the effect of inflammation on the Hb
and iron status outcomes.
The study, however, had several strengths, such as using
a fully randomized design, having active control groups, and
complete blinding of the laboratory workers involved in sample
collection and analysis. Our approach of measuring anemia
by using various Hb cutoffs was an added strength of the
study. As previously reported (12), the unintended exposure to
IFA or MMN supplements occurred on only 13% of follow-
up days, and no women in the LNS group were exposed to
any other supplement apart from the intended SQ-LNSs. We
compared several secondary outcomes simultaneously, and it
is possible that some of our findings may be due to chance
because of multiple testing (46). However, these outcomes were
prespecified, measured at the same time, and highly correlated,
and it was logical that they would be analyzed together (47).
Under these circumstances, correcting for multiplicity may be
unnecessary and counterproductive (46).
We chose ZPP concentration (i.e., ZPP:H ratio, expressed
as µmol/mol heme) as the indicator of children’s iron status
because it measures the adequacy of iron supply to the bone
marrow for Hb synthesis (48), and is able to detect iron
deficiency in the bone marrow at early stages (49, 50). In
infants, iron stores are often low or depleted (48) because of the
high iron requirement (51) for growth and development, and
in addition, iron stores may be depleted before absorption is
sufficiently upregulated.
It is noteworthy that infants in the 3 groups did not differ
in mean Hb concentration or iron status at 6 mo of age.
We previously reported (14) that mothers of infants in the
MMN and LNS groups, who consumed supplements with a
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TABLE 3 Unadjusted binary outcome measures (anemia and biomarkers of iron status) for infants in the iLiNS-DYAD randomized
trial of daily nutrient supplementation in a semiurban setting in Ghana, by intervention group1
Intervention groups based on supplements mothers
were intended to receive when enrolled
Intervention groups based on supplements mothers
actually received when enrolled
IFA
(n = 441)
MMN
(n = 439)
LNS
(n = 440) P2
IFA
(n = 441)
MMN
(n = 439)
LNS
(n = 440) P2
Anemia3
6 mo 37.1 (31.9, 42.6)
[310]
35.4 (30.4, 40.7)
[325]
33.5 (28.5, 39.0)
[313]
0.65 33.4 (28.4, 38.9)
[308]
38.8 (33.7, 44.2)
[327]
33.5 (28.5, 39.0)
[313]
0.26
18 mo 42.6 (37.4, 48.0)
[333]
47.3 (41.9, 52.7)
[328]
38.7 (33.6, 44.1)
[328]
0.09 43.9 (38.6, 49.4)
[321]
45.9 (40.6, 51.2)
[340]
38.7 (33.6, 44.1)
[328]
0.16
Anemia4
6 mo 19.7 (15.6, 24.5)
[310]
19.4 (15.4, 24.1)
[325]
16.6 (12.9, 21.2)
[313]
0.55 19.2 (15.1, 23.9)
[308]
19.9 (15.9, 24.6)
[327]
16.6 (12.9, 21.2)
[313]
0.54
18 mo 6.0 (3.9, 9.1)
[333]
4.9 (3.0, 7.8)
[328]
4.6 (2.8, 7.5)
[328]
0.68 5.6 (3.6, 8.7)
[321]
5.3 (3.4, 8.2)
[340]
4.6 (2.8, 7.5)
[328]
0.83
Elevated ZPP5
6 mo 31.7 (26.6, 37.2)
[300]
37.7 (32.5, 43.1)
[316]
35.8 (30.5, 41.4)
[299]
0.28 34.6 (29.4, 40.1)
[301]
34.9 (29.8, 40.4)
[315]
35.8 (30.5, 41.4)
[299]
0.95
18 mo 35.3 (30.3, 40.6)
[329]
34.7 (29.7, 40.0)
[323]
27.5 (22.9, 32.7)
[320]
0.07 36.6 (31.5, 42.0)b
[317]
33.4 (28.6,
38.7)ab [335]
27.5 (22.9, 32.7)a
[320]
0.046
IDA6
6 mo 19.0 (14.9, 23.8)
[300]
18.7 (14.7, 23.4)
[316]
19.7 (15.6, 24.6)
[299]
0.94 17.9 (14.0, 22.7)
[301]
19.7 (15.7, 24.5)
[315]
19.7 (15.6, 24.6)
[299]
0.82
18 mo 23.4 (19.1, 28.3)
[329]
21.4 (17.2, 26.2)
[323]
18.1 (14.3, 22.7)
[320]
0.25 23.3 (19.0, 28.3)
[317]
21.5 (17.4, 26.2)
[335]
18.1 (14.3, 22.7)
[320]
0.26
IDA7
6 mo 12.0 (8.8, 16.2)
[300]
11.7 (8.6, 15.8)
[316]
12.0 (8.8, 16.2)
[299]
0.99 11.6 (8.5, 15.8)
[301]
12.1 (8.9, 16.2)
[315]
12.0 (8.8, 16.2)
[299]
0.98
18 mo 4.9 (3.0, 7.8)
[329]
3.4 (1.9, 6.0)
[323]
3.4 (1.9, 6.1)
[320]
0.55 4.4 (2.6, 7.3)
[317]
3.9 (2.3, 6.6)
[335]
3.4 (1.9, 6.1)
[320]
0.82
1All supplements were intended for daily consumption. Results are based on logistic regression models (SAS PROC GLIMMIX). Values are percentages (95% CIs) of participants
identified as “yes” for the outcome in question [number of participants analyzed for the outcome in question]. Values in the same row without a common superscript letter are
significantly different at α = 0.05. IDA, iron deficiency anemia; IFA, Iron and Folic Acid group: infants were assigned to receive no supplements, their mothers were assigned to
receive 60 mg Fe/d and 400 µg folic acid/d during pregnancy and 200 mg Ca/d as placebo during the first 6 mo postpartum; iLiNS, International Lipid-based Nutrient Supplements;
LNS, Lipid-based Nutrient Supplement group: infants were assigned to receive 20 g Lipid-based Nutrient Supplement/d (designed for infants) containing 6 mg Fe/d from 6 to
18 mo of age, their mothers received 20 g Lipid-based Nutrient Supplement/d (designed for women) with the same micronutrients as the MMN group during pregnancy and
the first 6 mo postpartum—both LNS products contained 4 additional minerals (calcium, phosphorus, potassium, and magnesium) as well as macronutrients; MMN, Multiple
Micronutrient group: infants were assigned to receive no supplements, their mothers were assigned to receive a multiple micronutrient capsule containing 18 vitamins and
minerals, including 20 mg Fe, daily during pregnancy and the first 6 mo postpartum; ZPP, zinc protoporphyrin.
2P values compare all 3 groups, with Tukey–Kramer adjustment for pairwise comparisons.
3Anemia defined as blood hemoglobin <110 g/L (33).
4Anemia defined as blood hemoglobin <105 g/L for children at 6 mo of age (34), and blood hemoglobin <100 g/L for children at 18 mo of age (31, 34).
5Elevated ZPP considered indicative of iron deficiency was defined as ZPP >70 µmol/mol heme. This (moderate) cutoff is consistent with ZPP concentration >10th percentile
for preschool children (35–37).
6IDA was defined as blood hemoglobin <110 g/L and ZPP >70 µmol/mol heme (33, 35–37).
7IDA was defined as blood hemoglobin <105 g/L (34) and ZPP >70 µmol/mol heme (33, 35–37) for children at 6 mo of age, and blood hemoglobin <100 g/L (31, 34) and
ZPP >70 µmol/mol heme (33, 35–37) for children at 18 mo of age.
lower iron content (20 mg/d) than did those in the IFA group
(60 mg/d), had a lower mean Hb concentration, lower iron
status (higher mean ZPP and plasma transferrin receptor), and a
higher prevalence of anemia at 36 weeks of gestation. Therefore,
the infants in the MMN and LNS groups were expected to be
more likely than those in the IFA group to be anemic and/or to
have lower iron status (e.g., higher mean ZPP concentration)
by 6 mo of age, because of evidence that an infant’s risk of
developing anemia after birth is related to the mother’s anemia
and iron status at delivery (52–54), whereas maternal iron
intake postpartum does not affect breast-milk iron content (55).
On the other hand, infants in the LNS group were previously
reported to have a greater mean birth weight than those in the
IFA group (13), and thus may have had greater iron stores at
birth (52, 56). Our findings suggest that any risk of developing
anemia among children in the LNS group (and possibly the
MMN group) during the first 6 mo after delivery as a result of
their mothers consuming supplements with lower iron content
during pregnancy may have been offset through greater iron
stores resulting from increased birth weight. Few randomized
controlled trials have examined the impact of prenatal iron
supplementation on the Hb concentration or iron status of the
offspring during the first 6 mo of life (57). Our study provides
evidence that in this setting where iron deficiency in infancy is
common (58), the consumption of SQ-LNSs during pregnancy
(in comparison with the standard dose of iron and folic acid)
does not compromise theHb production or iron status of infants
at 6 mo of age. The extent to which the increased birth weight
in the LNS group contributed to the Hb concentration and iron
status at 6 mo of age requires further investigation.
From 6 to 18 mo of age, the iron dosage (6 mg/d) given to
infants in the LNS group was lower than that used in most home
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fortification trials (59) including our previous study in Ghana
(26). However, a similar dosage was used in SQ-LNS products
in a trial in Burkina Faso (60), where infants consuming these
products from 9 to 18 mo of age along with malaria and
diarrhea treatment had lower prevalence of anemia and iron
deficiency than did children who received no intervention. In
China, the consumption of a fortified food supplement contain-
ing 6 mg Fe/d by infants 4–12 mo of age increased the children’s
mean Hb concentration compared with the consumption of an
unfortified food supplement (61). Thus, it is likely that the iron
dosage used in the present study was adequate.
Our results on infants’ iron status at 18 mo of age are
consistent with those from Burkina Faso (60) and our previous
study in Ghana (62) showing that SQ-LNS supplementation
reduced the prevalence of iron deficiency when compared with
no supplementation for infants. In those 2 previous studies,
the percentage of children with low ferritin or elevated serum
transferrin receptor was lower among those who consumed SQ-
LNSs than among children who did not consume any supple-
ments, although the geometric mean ZPP concentration did not
differ between the intervention and nonintervention groups in
Burkina Faso (60), and ZPP was not measured in Ghana (62). A
previous meta-analysis demonstrated that home fortification of
complementary foods, including the use of SQ-LNSs, is effective
for the prevention of IDA (59). In the current study, there
were no significant differences in mean Hb concentration or
prevalence of anemia, which appears to contradict previous
results (60, 62). However, there was a trend for a difference
in anemia prevalence at 18 mo of age when comparing the
LNS group with the other 2 groups combined, equivalent to
a 14% reduction in the risk of anemia. A possible reason for
the lack of significant group differences could be that in the
current trial, children’s mean Hb concentration at 6 mo of age
(113 g/L) was relatively high, compared with that (107 g/L) in
the previous study in Ghana (62) or that (88 g/L) of the 9-mo-
old children in Burkina Faso (60). Thus, infants in this study
may have been less likely to demonstrate a response to SQ-LNSs
than infants in the other 2 studies (60, 62).
According to the Ghana Demographic and Health Survey
(GDHS) 2014 report (63), 78% of children 12–17 mo of
age and 74% of children 18–23 mo of age in Ghana were
anemic when using the WHO cutoff (Hb <110 g/L) to define
anemia. The relatively low anemia prevalence at 18 mo of
age observed in our trial (42.9%) therefore conflicts with
the GDHS 2014 report, perhaps because of regional and/or
subregional variations in the distribution of anemia prevalence
in Ghana, or methodological differences such as collection of
capillary as opposed to venous blood, use of different models of
the Hemocue photometer, or different protocols for handling
samples for measuring Hb concentration. It is unlikely that
the discrepancy is due to a decreasing secular trend of anemia
prevalence in Ghana, because the GDHS and our trial were
conducted around the same period of time.
Our observation that nearly 39% of the children in the LNS
group were anemic at 18 mo of age based on theWHO cutoff of
110 g/L, despite the SQ-LNS supplementation, warrants further
discussion. In West Africa including Ghana, the main causes
of anemia in children <5 y of age are iron deficiency, malaria,
schistosomiasis, sickle cell disorders, and hookworm infection
(in decreasing order of importance) (64). We do not have data
on sickle cell disorders, but given the low percentage (∼1% at
6 or 18 mo of age) of children who tested positive for malaria,
as well as the children’s young age of 18 mo, it is unlikely that
malaria, schistosomiasis, and hookworm infections contributed
substantially to anemia in our sample. Thus, nonresponsive
anemia in the LNS group might be due to poor iron absorption
or utilization attributable to factors including: antinutritional
compounds, e.g., phenolic compounds in the predominantly
plant-based diet reducing iron absorption (65–68); gastric
acid hyposecretion (69, 70) reducing iron absorption (71,
72); and hepcidin-induced inhibition of iron absorption and
transport due to inflammation (73, 74). Alternatively, the
WHO cutoff may be too high, leading to an overestimation
of anemia prevalence. When using a lower cutoff of <100
g/L, as recommended by INACG (31), anemia prevalence in
the LNS group at 18 mo of age was only 4.6%. In Ghana,
anemia prevalence in children (using the standard cutoff) has
remained high (63) and supposedly nearly unresponsive to
various malaria and helminth reduction interventions (75).
We conclude that maternal and infant supplementation with
SQ-LNSs increases infants’ iron status in this semiurban setting
in Ghana.More research is needed to investigate the lack of Hb
response to micronutrient supplementation among children in
this and similar settings, and to identify appropriate cutoffs for
defining anemia in children (76).
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